<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00266825</url>
  </required_header>
  <id_info>
    <org_study_id>10186</org_study_id>
    <secondary_id>R01HD047315</secondary_id>
    <nct_id>NCT00266825</nct_id>
  </id_info>
  <brief_title>DHA Supplementation and Pregnancy Outcome</brief_title>
  <official_title>Kansas University DHA Outcome Study (KUDOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susan Carlson, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if increasing DHA intake during pregnancy can
      increase gestation duration and enhance infant and childhood outcomes related to visual
      acuity, stereoacuity, attention, and distractibility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although numerous trials show benefits of postnatal DHA supplementation for visual acuity and
      others show benefits for cognitive function and/or attention, studies of increased DHA
      exposure during fetal life are needed, especially in the US. Women in the US consume low
      amounts of DHA compared to other world populations, and this likely means less DHA transfer
      to the fetus than in many other populations. Prenatal DHA exposure may be more important than
      postnatal exposure, because animal studies show critical windows for brain DHA accumulation
      in relation to effects on neurotransmitters such as serotonin, dopamine and GABA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Total Fatty Acids by Weight</measure>
    <time_frame>at time of birth</time_frame>
    <description>Measure of RBC-phospholipid-DHA at Birth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gestational Age</measure>
    <time_frame>at time of birth</time_frame>
    <description>Gestational age of babies at time of birth in days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Birth Weight</measure>
    <time_frame>at time of birth</time_frame>
    <description>Weight of baby at birth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Birth Length</measure>
    <time_frame>at time of birth</time_frame>
    <description>Length of baby at birth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ponderal Index</measure>
    <time_frame>at time of birth</time_frame>
    <description>Ponderal index calculated with formula Weight (g)/length (cm)^3 * 100. It a measure of leanness of a person and is calculated as a relationship between mass and height. Commonly used in pediatrics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender of Babies</measure>
    <time_frame>at time of birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cord RBC-phospholipid-DHA</measure>
    <time_frame>at time of birth</time_frame>
    <description>Percentage of total fatty acids by weight in cord RBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head Circumference</measure>
    <time_frame>at time of birth</time_frame>
    <description>Measure of circumference of baby's head in centimeters at time of birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm Births</measure>
    <time_frame>births before week 37 of gestation</time_frame>
    <description>Percentage of births occurring at less than 37 weeks of gestation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>DHA capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHA capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHA</intervention_name>
    <description>600 mg DHA</description>
    <arm_group_label>DHA capsules</arm_group_label>
    <other_name>docosahexaenoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant 8-20 wks at enrollment

          -  single fetus

          -  BMI &lt;40

        Exclusion Criteria:

          -  diabetes (Type I, ii, GDM)

          -  hypertension (primary, PIH, preeclampsia/eclampsia)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan E Carlson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Colombo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Truman Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Carlson SE, Colombo J, Gajewski BJ, Gustafson KM, Mundy D, Yeast J, Georgieff MK, Markley LA, Kerling EH, Shaddy DJ. DHA supplementation and pregnancy outcomes. Am J Clin Nutr. 2013 Apr;97(4):808-15. doi: 10.3945/ajcn.112.050021. Epub 2013 Feb 20.</citation>
    <PMID>23426033</PMID>
  </results_reference>
  <results_reference>
    <citation>Ozias MK, Kerling EH, Christifano DN, Scholtz SA, Colombo J, Carlson SE. Typical prenatal vitamin D supplement intake does not prevent decrease of plasma 25-hydroxyvitamin D at birth. J Am Coll Nutr. 2014;33(5):394-9. doi: 10.1080/07315724.2013.879843. Epub 2014 Oct 10.</citation>
    <PMID>25302772</PMID>
  </results_reference>
  <results_reference>
    <citation>Scholtz SA, Kerling EH, Shaddy DJ, Li S, Thodosoff JM, Colombo J, Carlson SE. Docosahexaenoic acid (DHA) supplementation in pregnancy differentially modulates arachidonic acid and DHA status across FADS genotypes in pregnancy. Prostaglandins Leukot Essent Fatty Acids. 2015 Mar;94:29-33. doi: 10.1016/j.plefa.2014.10.008. Epub 2014 Nov 7.</citation>
    <PMID>25500337</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2005</study_first_submitted>
  <study_first_submitted_qc>December 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2005</study_first_posted>
  <results_first_submitted>June 30, 2015</results_first_submitted>
  <results_first_submitted_qc>January 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2016</results_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Susan Carlson, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from the Kansas City metro area. Enrollment occurred between January 2006 and November 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Capsule</title>
          <description>Placebo capsule
Placebo capsule: Placebo capsule</description>
        </group>
        <group group_id="P2">
          <title>DHA Supplement</title>
          <description>DHA capsule
DHA: 600 mg DHA</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Enrolled and Allocated Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Completed Follow-Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Capsule</title>
          <description>Placebo capsule
Placebo capsule: Placebo capsule</description>
        </group>
        <group group_id="B2">
          <title>DHA Supplement</title>
          <description>DHA capsule
DHA: 600 mg DHA</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="172"/>
            <count group_id="B2" value="178"/>
            <count group_id="B3" value="350"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" spread="4.7"/>
                    <measurement group_id="B2" value="25.3" spread="4.9"/>
                    <measurement group_id="B3" value="25.0" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race of mother</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Ethnicity of mother</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestation at Enrollment</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.6" spread="26.1"/>
                    <measurement group_id="B2" value="102.9" spread="25.3"/>
                    <measurement group_id="B3" value="101.3" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Total Fatty Acids by Weight</title>
        <description>Measure of RBC-phospholipid-DHA at Birth</description>
        <time_frame>at time of birth</time_frame>
        <population>The effect of DHA supplementation on study primary outcomes was determined for black and non-black subjects separately. Researchers did not compare outcomes between black and non-black subjects to determine whether they were statistically different. For measures reporting black and non-black results, there were 184 non-black and 117 black subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo capsule: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>DHA Supplement</title>
            <description>DHA capsule
DHA: 600 mg DHA</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Total Fatty Acids by Weight</title>
          <description>Measure of RBC-phospholipid-DHA at Birth</description>
          <population>The effect of DHA supplementation on study primary outcomes was determined for black and non-black subjects separately. Researchers did not compare outcomes between black and non-black subjects to determine whether they were statistically different. For measures reporting black and non-black results, there were 184 non-black and 117 black subjects.</population>
          <units>percentage of fatty acid</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.3"/>
                    <measurement group_id="O2" value="7.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Black Subjects (n=93, 112))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.3"/>
                    <measurement group_id="O2" value="7.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Subjects (n=79, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.3"/>
                    <measurement group_id="O2" value="6.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ponderal Index</title>
        <description>Ponderal index calculated with formula Weight (g)/length (cm)^3 * 100. It a measure of leanness of a person and is calculated as a relationship between mass and height. Commonly used in pediatrics.</description>
        <time_frame>at time of birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo capsule: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>DHA Supplement</title>
            <description>DHA capsule
DHA: 600 mg DHA</description>
          </group>
        </group_list>
        <measure>
          <title>Ponderal Index</title>
          <description>Ponderal index calculated with formula Weight (g)/length (cm)^3 * 100. It a measure of leanness of a person and is calculated as a relationship between mass and height. Commonly used in pediatrics.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.4"/>
                    <measurement group_id="O2" value="2.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Gestational Age</title>
        <description>Gestational age of babies at time of birth in days</description>
        <time_frame>at time of birth</time_frame>
        <population>The effect of DHA supplementation on study primary outcomes was determined for black and non-black subjects separately. Researchers did not compare outcomes between black and non-black subjects to determine whether they were statistically different. For measures reporting black and non-black results, there were 184 non-black and 117 black subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo capsule: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>DHA Supplement</title>
            <description>DHA capsule
DHA: 600 mg DHA</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Age</title>
          <description>Gestational age of babies at time of birth in days</description>
          <population>The effect of DHA supplementation on study primary outcomes was determined for black and non-black subjects separately. Researchers did not compare outcomes between black and non-black subjects to determine whether they were statistically different. For measures reporting black and non-black results, there were 184 non-black and 117 black subjects.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272.8" spread="17.0"/>
                    <measurement group_id="O2" value="275.7" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Black Subjects (n=93,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.8" spread="14.0"/>
                    <measurement group_id="O2" value="275.9" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Subjects (n=79,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271.4" spread="20.3"/>
                    <measurement group_id="O2" value="275.2" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Birth Weight</title>
        <description>Weight of baby at birth</description>
        <time_frame>at time of birth</time_frame>
        <population>The effect of DHA supplementation on study primary outcomes was determined for black and non-black subjects separately. Researchers did not compare outcomes between black and non-black subjects to determine whether they were statistically different. For measures reporting black and non-black results, there were 184 non-black and 117 black subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo capsule: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>DHA Supplement</title>
            <description>DHA capsule
DHA: 600 mg DHA</description>
          </group>
        </group_list>
        <measure>
          <title>Birth Weight</title>
          <description>Weight of baby at birth</description>
          <population>The effect of DHA supplementation on study primary outcomes was determined for black and non-black subjects separately. Researchers did not compare outcomes between black and non-black subjects to determine whether they were statistically different. For measures reporting black and non-black results, there were 184 non-black and 117 black subjects.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3187" spread="602"/>
                    <measurement group_id="O2" value="3359" spread="524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Black Subjects (n=93,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3282" spread="529"/>
                    <measurement group_id="O2" value="3489" spread="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Subjects (n=79,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3060" spread="671"/>
                    <measurement group_id="O2" value="3110" spread="559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Birth Length</title>
        <description>Length of baby at birth</description>
        <time_frame>at time of birth</time_frame>
        <population>The effect of DHA supplementation on study primary outcomes was determined for black and non-black subjects separately. Researchers did not compare outcomes between black and non-black subjects to determine whether they were statistically different. For measures reporting black and non-black results, there were 184 non-black and 117 black subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo capsule: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>DHA Supplement</title>
            <description>DHA capsule
DHA: 600 mg DHA</description>
          </group>
        </group_list>
        <measure>
          <title>Birth Length</title>
          <description>Length of baby at birth</description>
          <population>The effect of DHA supplementation on study primary outcomes was determined for black and non-black subjects separately. Researchers did not compare outcomes between black and non-black subjects to determine whether they were statistically different. For measures reporting black and non-black results, there were 184 non-black and 117 black subjects.</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" spread="3.4"/>
                    <measurement group_id="O2" value="49.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Black Subjects (n=93,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" spread="2.9"/>
                    <measurement group_id="O2" value="50.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Subjects (n=79,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" spread="4.0"/>
                    <measurement group_id="O2" value="49.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gender of Babies</title>
        <time_frame>at time of birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo capsule: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>DHA Supplement</title>
            <description>DHA capsule
DHA: 600 mg DHA</description>
          </group>
        </group_list>
        <measure>
          <title>Gender of Babies</title>
          <units>percentage of babies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cord RBC-phospholipid-DHA</title>
        <description>Percentage of total fatty acids by weight in cord RBC</description>
        <time_frame>at time of birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo capsule: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>DHA Supplement</title>
            <description>DHA capsule
DHA: 600 mg DHA</description>
          </group>
        </group_list>
        <measure>
          <title>Cord RBC-phospholipid-DHA</title>
          <description>Percentage of total fatty acids by weight in cord RBC</description>
          <units>percentage of cord RBC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="1.4"/>
                    <measurement group_id="O2" value="7.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Head Circumference</title>
        <description>Measure of circumference of baby's head in centimeters at time of birth.</description>
        <time_frame>at time of birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo capsule: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>DHA Supplement</title>
            <description>DHA capsule
DHA: 600 mg DHA</description>
          </group>
        </group_list>
        <measure>
          <title>Head Circumference</title>
          <description>Measure of circumference of baby's head in centimeters at time of birth.</description>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="2.0"/>
                    <measurement group_id="O2" value="34.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preterm Births</title>
        <description>Percentage of births occurring at less than 37 weeks of gestation.</description>
        <time_frame>births before week 37 of gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo capsule: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>DHA Supplement</title>
            <description>DHA capsule
DHA: 600 mg DHA</description>
          </group>
        </group_list>
        <measure>
          <title>Preterm Births</title>
          <description>Percentage of births occurring at less than 37 weeks of gestation.</description>
          <units>percentage of births</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Researchers followed the mother for 30 days post-partum and the infant from birth to 18 months. Typical follow-up stops 30 days after the end of the intervention. Researchers collected information on each from their medical records.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Capsule - Mother</title>
          <description>Placebo capsule
Placebo capsule: Placebo capsule</description>
        </group>
        <group group_id="E2">
          <title>Placebo Capsule - Infant</title>
          <description>Infants born from Mothers in the Placebo capsule group</description>
        </group>
        <group group_id="E3">
          <title>DHA Capsule - Mother</title>
          <description>DHA capsule
DHA: 600 mg DHA</description>
        </group>
        <group group_id="E4">
          <title>DHA Capsule - Infant</title>
          <description>Infants born from Mothers in the DHA capsule group</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital anomalies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Hospitalization or miscarriage</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hospitalization and death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="26" subjects_affected="26" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Postpartum hospitalization</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Susan Carlson</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-5359</phone>
      <email>SCARLSON@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

